Trygg Pharma AS, a company jointly owned by Norwegian biotechnology company Aker BioMarine ASA and New York-based investment fund Lindsay Goldberg, has acquired omega 3 supplier EPAX AS from Austevoll Seafood ASA.

“EPAX is fortunate to get an owner that will invest significantly in people, products, processes and technology in Aalesund,” said Bjørn Refsum, managing director of EPAX. “This ownership change will be a great benefit to our customers and ensure further progress in the omega 3 field.”

Mr. Refsum noted that throughout EPAX’s 170-year corporate history, ownership changes have naturally occurred and that the company’s experiences from these processes have always been positive.

“Trygg Pharma’s ownership will open up new opportunities and markets. Combining resources with such a highly regarded company that places major emphasis on research and development will benefit our customers, employees and partners and is making EPAX even stronger,” said Mr. Refsum.

As part of the agreement between Trygg Pharma AS and Austevoll Seafood, EPAX has entered into a long-term supply agreement with Austral S.A., a subsidiary of Austevoll Seafood. The agreement will ensure continued cooperation between EPAX and Austral, and secure supply of crude fish oil from sustainable and traceable sources.

Under its new ownership, EPAX will immediately invest significantly in expanding the capacity of the factory in Aalesund, Norway. “The planned capacity expansion means that our customers can rest assured that EPAX will be able to grow with them in the future,” said Mr. Refsum.